UM‐SCC‐104: A New human papillomavirus‐16–positive cancer stem cell–containing head and neck squamous cell carcinoma cell line by Tang, Alice L. et al.
ORIGINAL ARTICLE
UM-SCC-104: A New human papillomavirus-16–positive cancer stem cell–containing
head and neck squamous cell carcinoma cell line
Alice L. Tang, MD,1 Samantha J. Hauff, MD,1 John H. Owen, MS,1 Martin P. Graham, BS,1 Michael J. Czerwinski,1 Jung Je Park, MD, PhD,2
Heather Walline, MA,3,6 Silvana Papagerakis, MD, PhD,1 Jay Stoerker, PhD,3,4 Jonathan B. McHugh, MD,5 Douglas B. Chepeha, MD,1
Carol R. Bradford, MD,1 Thomas E. Carey, PhD,1* Mark E. Prince, MD1
1Department of Otolaryngology—Head & Neck Surgery, University of Michigan, Ann Arbor, Michigan, 2Department of Otolaryngology, Institute of Health Sciences, School of
Medicine, Gyeongsang National University, Jin Ju, South Korea, 3Sequenom Molecular Medicine Laboratory, Ann Arbor, Michigan, 4Vice President and Laboratory Director,
aMDX Laboratory Sciences, Farmington Hills, Michigan, 5Department of Pathology, University of Michigan, Ann Arbor, Michigan, 6Pre-Doctoral Candidate Graduate Program in
Cancer Biology, The University of Michigan School of Medicine, Ann Arbor, Michigan.
Accepted 6 September 2011
Published online 13 December 2011 in Wiley Online Library (wileyonlinelibrary.com). DOI 10.1002/hed.21962
ABSTRACT: Background. Few human papillomavirus (HPV)(þ) head and
neck squamous cell carcinoma (HNSCC) cell lines exist. We established
University of Michigan-squamous cell carcinoma-104 (UM-SCC-104), a new
HPV(þ) HNSCC cell line from a recurrent oral cavity tumor, and
characterized it for the presence of cancer stem cells (CSCs).
Methods. Tumor cells were tested for biomarker expression by
immunohistology, and the presence of HPV was assessed by several
methods.
Results. UM-SCC-104 has a unique genotype, contains HPV-16, and
expresses E6/E7. Inoculation of aldehyde dehydrogenase (ALDH)(þ) and
ALDH() cells in an immunocompromised mouse resulted in tumor
growth from the ALDH(þ) cells after 6 weeks that recapitulated the
histology of the primary, whereas ALDH() cells did not produce
tumors.
Conclusion. UM-SCC-104, a new HPV-16, CSC-containing HNSCC cell
line will aid in studying recurrent HPV(þ) tumors. The aggressive nature
of this tumor is consistent with high uniform expression of epidermal
growth factor receptor (EGFR) and a functionally significant proportion of
ALDH(þ) CSCs. VC 2011 Wiley Periodicals, Inc. Head Neck 34:
1480–1491, 2012
KEY WORDS: HNSCC, HPV, cancer stem cells, head and neck cell
lines, ALDH
The establishment of cell lines from primary tumors is
essential to head and neck squamous cell cancer
(HNSCC) research. While many cell lines have been suc-
cessfully established in the last 30 years,1–3 there are few
that have been derived from cancers naturally infected
with high-risk human papillomavirus (HR-HPV) in the
head and neck. In recent years, it has become clear that
the overwhelming majority of oropharyngeal tumors are
now associated with HR-HPV and there is strong evi-
dence that the presence of HR-HPV in the tumor is an in-
dependent prognostic factor in overall survival for
patients diagnosed with HNSCC.4,5 However, not all
patients with HPV(þ) tumors respond well to therapy and
the reasons for failure in some cases are not known.6,7 The
availability of HR-HPV-containing cell lines enhances our
ability to study the role that HPV plays in HNSCC devel-
opment and response or resistance to therapy.
The selective pressure on cells in the formation of an
immortal cell line has been discussed previously.2,8,9
There are limitations in using cell line behavior to reflect
that of the original tumor because it is speculative that cell
lines truly reflect the behavior of primary tumors. How-
ever, despite this, it is well documented that cell lines
remain the fundamental tools for preclinical investigations
in the most efficient and cost-effective way. Other preclin-
ical models, such as the use of xenografts, are equally val-
uable and important to investigate cancer cell behavior;
however, cell lines avoid high cost and ethical issues that
inevitably arise when using animal models.
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Our group and others have studied biomarker expression
in HNSCC in HPV(þ) and HPV() tumors, with HPV and
p16INK4a emerging as biomarkers associated with improved
prognosis in oropharyngeal cancer.7,10–12 Epidermal
growth factor receptor (EGFR), p53, and Bcl-xL are also
relevant markers that modify the prognostic effect of HPV
and may help guide the development of targeted therapy in
HNSCC.6,10 CDKN2a encodes the cyclin-dependent kinase
inhibitor p16INK4a, which is almost always overexpressed in
HPV(þ) oropharyngeal tumors, and is often lost or silenced
in HPV() head and neck tumors13 with only rare examples
of p16INK4a positive/HPV() tumors.14 Overexpression of
p16INK4a, like HPV, is an independent positive prognostic
indicator for HNSCC.15 E-cadherin and nuclear b-catenin
may also play a role in tumor progression in HPV-related
tumors, and studies of these biomarkers may help to eluci-
date differences in tumor biology between HPV(þ) and
HPV() tumors.16 In our characterization, we chose to look
at biomarkers that have been studied before and implicated
in HNSCC prognosis.
Cancer stem cells (CSCs) have been isolated in
HNSCC using the cellular expression of aldehyde
dehydrogenase (ALDH activity).17–19 The ALDHþ CSC
subpopulation (also called the tumor initiating cell popu-
lation) is highly tumorigenic, can self-renew, and has the
capacity to recreate the initial tumor heterogeneity. De-
velopment of therapeutic strategies targeting CSC path-
ways necessitates identification of this important subpo-
pulation in primary tumors and cell lines.20 In effect,
distinguishing CSCs in new and existing cell lines is par-
amount to developing novel approaches in targeting these
cancer-initiating cells. In this article, we describe the de-
velopment and characterization of a new HPV(þ)
HNSCC cell line that contains a tumorigenic CSC
population.
MATERIALS AND METHODS
Approvals for use of the animal model were obtained
through the University of Michigan Committee for the
Humane Care and Use of Animals. The University of
Michigan’s Guide for the Care and Use of Laboratory Ani-
mals was followed.
Establishment of the cell line
Written informed consent was obtained from the patient
for the study of his tissue and medical records after
review and approval of the study and the consent form by
the Medical School Institutional Review Board. Surgically
resected tumor tissue was carefully selected for culture by
the surgeon (D. B. C.), immediately transported to the
laboratory, and was washed extensively in Earle’s bal-
anced salt solution containing penicillin, streptomycin,
and amphotericin B. The tissue was then minced, placed
in culture flasks, and covered with complete Dulbecco’s
modified Eagle’s medium containing 10% fetal bovine se-
rum, L-glutamine, penicillin, and streptomycin.2,3 The tu-
mor was heavily infected with yeast, therefore, amphoter-
icin B (20 lg/mL) was also added to the medium and
frequent washing was used to remove as much of the
yeast as possible with each medium change. Eventually,
sterile cultures were obtained and propagated. Trypsin
with 0.125% EDTA was used for partial trypsinization to
aid in fibroblast removal. When sufficient outgrowth of
cells was observed, cells were detached using warm tryp-
sin and plated into new culture flasks. The cells have
been carried through multiple passages. Supernatants
were tested for mycoplasma using Myco Alert Myco-
plasma Testing Kit (Lonza, Rockland, ME).
Analysis of genetic loci
DNA was extracted from University of Michigan-squa-
mous cell carcinoma (UM-SCC-104) tumor cells and from
fibroblasts separated from the UM-SCC-104 culture during
cell line establishment using a modified Promega Wizard
protocol (Promega, Madison, WI). Briefly, the genotyping
procedure is as follows: cell pellets are re-suspended in
Nuclei Lysis Solution at 55C. Proteins are precipitated,
vortexed, then chilled on ice and separated by centrifuga-
tion at 13K revolutions per minute. DNA in the lysis super-
natant is precipitated with isopropanol, diluted to 0.10 ng/
lL and submitted to the University of Michigan Sequenc-
ing Core for analysis with the Profiler Plus PCR Amplifica-
tion Kit (Applied Biosystems, Foster City, CA). Ten loci
are analyzed: D3S1358, vWA, FGA, D8S1179, D21S11,
D18S51, D5S818, D13S317, and D7S820, and the amelo-
genin locus for identifying the presence of the X and Y
chromosomes. Polymerase chain reaction (PCR) products
are analyzed using the Applied Biosciences 3730 DNA
sequencer and allele sizes are detected fluorescently.
Flow cytometry
ALDH activity was detected using the Aldefluor kit
(Stem Cell Technologies, Vancouver, British Columbia,
Canada). Briefly, cells from the primary tumor were
brought to single cell suspension in Aldefluor assay buffer,
and incubated with ALDH substrate (Bodipy aminoacetal-
dehyde (BAAA), 5 lmol/L per 1  106 cells) for 45
minutes at 37C. Concurrently, diethylaminobenzaldehyde
(DEAB 50 mmol/L) was added to a separate sample also
containing BAAA for an ALDH-inhibited control. Samples
were washed and resuspended in Aldefluor assay buffer.
We used 40, 6-diamidino-2-phenylindole (BD Pharmingen,
San Diego CA) as a cell viability indicator. Fluorescence-
activated cell sorting gates were established using the
inhibited control (DEAB) and the cell viability sample dia-
midino-2-phenylindole.
In vivo tumor production from cancer stem cells
ALDHHigh and ALDHLow fractions from UM-SCC-104
were collected into separate tubes and 5000 cells from
each fraction were suspended in 100 lL of Dulbecco’s
modified Eagle’s medium with 100 lL of Matrigel (BD
Biosciences, San Jose, CA) for in vivo injections. The
resulting 200 lL cell suspensions were injected subcuta-
neously into opposite flanks of a nonobese diabetic/severe
combined immunodeficiency (NOD/SCID) mouse (strain
#001303, Jackson Laboratories, Bar Harbor, ME). Tumor
grown from the ALDHHigh inoculation was allowed to
persist until the growth reached 1 cm in size (10 weeks)
and subsequently harvested for sectioning. The tumor tis-
sue was excised, washed in sterile phosphate-buffered sa-
line, transferred to 70% ethanol, and delivered to the Uni-
versity of Michigan Research Histology and
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Immunoperoxidase Laboratory for automated vacuum
infiltration tissue processing (Tissue Tek VIP 5, Sakura
Finetek USA, Torrance, CA) in graded ethanol 70% for
15 minutes, 95% for 15 minutes, 100% 15  2, followed
by xylene and 4 cycles of paraffin infiltration and
sectioning.
Immunohistochemistry
UM-SCC-104 cells were cultured on chamber slides
until 50% confluent and then were fixed and permeabil-
ized with 4% paraformaldehyde and 0.1% Triton-x for 15
minutes for each step (Sigma, St. Louis, MO). Fixed
slides were kept in phosphate-buffered saline at 4C until
staining. Tissue slides from the surgical specimen and
from the primary tumor murine xenograft were deparaffi-
nized, rehydrated, and peroxidase-quenched (Dako Cyto-
mation, Glostrup, Denmark). All slides except for 1 were
incubated in Antigen Retrieval Solution (Dako Cytoma-
tion) for 40 minutes in a 92C water bath with a buffer
change midway and allowed to cool to room temperature
for 20 minutes. For EGFR, the antigen retrieval step was
performed with pepsin incubation for 10 minutes at 37C.
Horse serum was used for blocking (30 minutes at room
temperature). Sections were stained with primary antibod-
ies: monoclonal mouse anti-EGFR/31G7 (Invitrogen,
Camirillo, CA), monoclonal mouse anti-Bcl-2/124 (Dako
Cytomation), monoclonal mouse anti-p53/DO1 (Calbio-
chem, Darmstadt, Germany), monoclonal rabbit anti-
cyclin D1/SP4, and monoclonal mouse anti-Rb/51B7
(Neomarkers, Fremont, CA). Primary antibodies were
added and allowed to incubate overnight at 4C. Staining
for p16INK4a was performed per protocol supplied by the
kit (CINtec p16INK4a Histology Kit; mtm Laboratories,
Westborough, MA). Slides were washed and incubated
with corresponding biotinylated secondary antibodies
(Vector Laboratories, Burlingame, CA) at 1:200 dilution
for 30 minutes. The slides were washed and incubated in
a solution of coupled avidin/horseradish peroxidase (ABC
Kit; Vector Laboratories), allowing linkage to the second-
ary antibodies via avidin-biotin binding. After washing, a
DAB Peroxidase Substrate Kit (Vector Laboratories) was
used to detect primary antibody binding. After a final
washing step in tap water, the specimens were dehydrated
and mounted. The stained slides were interpreted by a pa-
thologist (J. B. McHugh).
Human papillomavirus detection and human
papillomavirus type identification
DNA was isolated from UM-SCC-104 and from the
primary tumor tissue using DNeasy Blood and Tissue Kit
(Qiagen). The presence and type of high risk HPV DNA
was detected using the Mass Array technique developed
by Dr. David Kurnit modified as described herein.21 Mul-
tiplex PCR amplification of the E6 region of 15 discrete
high-risk HPV types (HPV 16, 18, 31, 33, 35, 39, 45, 51,
52, 56, 58, 59, 66, 68, and 73), as well as a human glyc-
eraldehyde 3-phosphate dehydrogenase (GAPDH) control
(Table 1A for a list of primers) was run to saturation fol-
lowed by shrimp alkaline phosphatase quenching. Ampli-
fication reactions included a competitor oligonucleotide
identical to each natural amplicon except for a single nu-
cleotide difference. Shrimp alkaline phosphatase removes
TABLE 1. Primer sequences.
Primer Sequence
A. Primers used for identifying unique sequences in the E6 region





























































Abbreviations: HPV, human papillomavirus; F, forward primer; R, reverse primer; E, extension
primer; GAPDH, glyceraldehyde 3-phosphate dehydrogenase; RT-PCR, reverse transcriptase-
polymerase chain reaction.
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phosphate from residual free dNTPs in the reaction mix-
ture to prevent their incorporation in the next step, a sin-
gle base extension reaction, which uses terminal bases.
This multiplex single base extension reaction uses probes
(primer E, Table 1A) that identify unique sequences in
the E6 region of each type, extending at the single base
difference between wild-type and competitor HPV. The
extension PCR product from each HPV type and its com-
petitor can then be distinguished by mass (40 or 80 Dal-
ton difference between wild type and competitor) when
analyzed on the matrix assisted laser desorption ioniza-
tion-time of flight (MALDI-TOF) mass spectrometer21,22
(Figure 1). In situ hybridization was carried out in the pa-
thology laboratory on formalin-fixed paraffin-embedded
sections of the resected tumor using the INFORM HPVIII
ISH assay (Ventana, Tucson, AZ), which consists of a
FIGURE 1. PCR-MassARRAY using MALDI-TOF mass spectroscopy to detect and type human papillomavirus. Diagram depicting three-step
process of HPV detection by competitive multiplex PCR amplification using 15 hrHPV type-specific primer pairs for HPV E6 & hGAPDH.
Amplification of HPVE6 occurs in episomal and/or integrated viral DNA as well as each of the synthetic competitors. PCR, polymerase chain
reaction; hrHPV, high-risk human papillomavirus; HPV, human papillomavirus; GAPDH, glyceraldehyde 3-phosphate dehydrogenase; MALDI, matrix
assisted laser desorption ionization; TOF, time of flight.
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cocktail directed against 12 high-risk HPV genotypes
(HPV 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, and 66).
RNA extraction, reverse transcription polymerase chain
reaction, gene sequencing
RNA from UM-SCC-104 was isolated by phenol-chlo-
roform extraction with TRIzol (Invitrogen). cDNA was
synthesized using Reverse Transcription System Kit
(Promega) in accord with the manufacturer’s protocol,
and detection of p53, E6, and E7 was performed using
primers listed in Table 1B. The HPV-16-containing CaSki
cervical carcinoma cell line and the HPV-16(þ) UM-
SCC-47 oropharyngeal carcinoma cell line developed in
our laboratory23 were used as positive controls and the
known HPV() cell line UM-SCC-38 was used as a neg-
ative control for E6 and E7 (amplicon sizes 477 base
pairs and 400 base pairs, respectively; Table 1B for pri-
mers). The complete p53 cDNA was sequenced with 3
overlapping primer sets: amplicon 1 (652 base pairs),
amplicon 2 (719 base pairs), and amplicon 3 (534 base
pairs; Table 1C for primers). PCR products were submit-
ted to the University of Michigan Sequencing Core for
target gene sequencing. cDNA sequencing covers the
entire p53 transcript including all exons and is the pre-
ferred method of sequencing as it can identify splicing




UM-SCC-104 was derived from a 56-year-old man
with a recurrent floor of mouth squamous cell carcinoma.
He was initially treated at a different hospital in 2008
with wide local excision for a posterior sublingual tumor
that was described as moderately to poorly differentiated
squamous cell carcinoma. Four months later, he had a
second wide local excision of a recurrent tumor of the
floor of mouth and, because of continuing suspicion of
persistent disease in the floor of mouth–mandibular
alveolus, he was treated with chemoradiation (no details
were available on the agents used, the doses, or duration
of treatment). After the completion of radiation, the
FIGURE 2. Establishment of UM-SCC-104 from a recurrent oral cavity squamous cell carcinoma. A, Outgrowths of squamous cells from explanted
tissue placed in culture flasks. B, UM-SCC-104 at passage 8 growing in separate colonies which is its typical phenotype. C, Tumor tissue section
from the patient stained with hematoxylin and eosin demonstrating infiltrating nests of tumor cells with abundant pink (keratinized) cytoplasm.
Histology also showed intercellular bridges and focal squamous whorls typical of squamous cell carcinoma. D, Tumor tissue section (H and E
stained) from xenograft derived from UM-SCC-104 cells expressing high ALDH expression. Like the patient’s tumor section, the morphology of the
xenograft consists of infiltrating nests of tumor cells with abundant pink (keratinized) cytoplasm and occasional squamous whorls consistent with
the patient’s poorly differentiated squamous carcinoma. [Color figure can be viewed in the online issue, which is available at
wileyonlinelibrary.com.]
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patient was referred to the University of Michigan where
he presented with a painful erosive sublingual mass
involving the mandibular alveolus and the lateral tongue
and his disease was restaged as T4 N2b M0. Composite
resection of the anterior mandible and anterior two thirds
of the tongue, and reconstruction procedures with an
osseus fibular and myocutaneous lattissimus dorsi flap
were performed with bilateral selective neck dissections.
The patient gave written informed consent for research on
his tissue. Tissue from the resected oral cavity tumor was
sent to the laboratory for culture and analysis. Three
months after this surgery, there was an aggressive local
recurrence deep to the reconstruction that was deemed
unresectable. The patient returned home on palliative
care. The patient’s social history was reported as 2 packs
of cigarettes per day for 20 years and 2 alcoholic drinks
per day. He was a nonsmoker at the time of treatment for
his cancer.
University of michigan-squamous cell carcinoma-104
Explanted tissue produced outgrowths of cells approxi-
mately on day 7 of culture (Figure 2A). At this point,
multiple culture flasks were found to contain yeast, and
amphotericin B was added to the culture medium. Cul-
tures were fed and rinsed with amphotericin B–containing
medium until cultures no longer contained the contami-
nant. Differential trypsinization successfully removed
fibroblast overgrowth leaving behind the epithelial cells.
By day 21, the first passage of tumor cells to new flasks
could be accomplished. The tumor cells were frozen at
multiple low passages and were considered established as
a cell line after the passage 20 milestone. UM-SCC-104
has a doubling time of 48 hours. Separate colony forma-
tion is typical of UM-SCC-104, and colonies will not
become over-confluent (Figure 2B). This mirrors the his-
tologic appearance of the grape-like clusters of tumor
cells in the patient’s anterior floor of mouth lesion tumor
tissue, which was determined to be a moderately to
poorly differentiated invasive squamous cell carcinoma
(Figure 2C). This histologic appearance was recapitulated
in subcutaneous tumors produced in the mouse after inoc-
ulation of ALDHHigh tumor cells (Figure 2D).
University of michigan-squamous cell carcinoma-104
genotype
The genotype of UM-SCC-104 is unique among the ge-
notypes of our entire collection of cell lines.23 As shown
in Table 2, the genotype of the UM-SCC-104 cell line
and the fibroblasts that grew out from the normal stroma
are nearly identical, except that the tumor cells show loss
of 1 allele at each of 2 loci, D3S1358 and FGA.
Cancer stem cell derived xenograft
UM-SCC-104 cells sorted for ALDH expression
revealed a 2.3% ALDHHigh population (Figure 3A and
3B). Cells selected for high and low ALDH activity were
inoculated subcutaneously into opposite sides of NOD/
SCID mice. Tumor growth resulted from the
ALDHHigh injection after 6 weeks (Figure 3C and 3D)
whereas no growth was observed from the ALDHLow
injection even after 10 weeks of observation at which
time the tumor from the ALDHHigh inoculation was har-
vested. Xenograft tissue morphology consisted of thick
cords and clusters of poorly differentiated squamous cells
similar to those in the tumor tissue taken from the patient
(compare Figure 2C and 2D).
Head and neck cancer biomarkers
Figure 4 shows a comparison of biomarker expression
in the patient’s tumor tissue, the murine xenograft, and
the UM-SCC-104 cell line. Sections of the resected tumor
tissue had weak expression of Rb and Bcl-2. In the xeno-
graft tumor, Rb was expressed only in mitotic cells, but
in the cell line all nuclei strongly expressed Rb. Bcl-2
also was not detected in the xenograft but is expressed in
nuclei and cytoplasm of many cells in the UM-SCC-104
cell line, with the strongest expression in mitotic nuclei.
The p53 overexpression is present in a subset of the
nuclei of the patient’s tumor, in a lower proportion of the
xenograft cells, and in a high proportion of nuclei in the
cell line. Similarly, cyclin D expression is found in focal
areas in the patient tumor and the xenograft, but is
strongly expressed in nearly all of the cells in the cell
line. All cells within the patient tumor, xenograft, and the
cell line strongly express diffuse nuclear and cytoplasmic
p16INK4a. Similarly, all cells in the tumor, the xenograft,
and the cell line exhibit strong and diffuse membranous
staining for EGFR.
Human papillomavirus and p53 status
In situ hybridization on the patient’s tumor demon-
strated scattered cells with large punctate nuclear signals
consistent with the presence of integrated HPV DNA (Fig-
ure 5A). In comparison, an adjacent section cut from the
same block at the same time exhibited strong p16 staining
in all tumor cells (Figure 5B). The presence of HPV in
DNA from the patient’s tumor and the UM-SCC-104 cell
line was confirmed and identified as HPV-16 by PCR-
MassARRAY with MALDI-TOF mass spectroscopy (Fig-
ure 6). Expression of strong HPV-16 E6 and E7 onco-
genes were demonstrated by reverse transcriptase-poly-
merase chain reaction (RT-PCR) in UM-SCC-104 and in
the HPV-16 positive controls, Caski and UM-SCC-47 cell
lines (Figure 7). The HPV-16 E6 primer set amplifies both
TABLE 2. Genotyping results for UM-SCC-104.
Passage AMEL D3S1358 vWA FGA D8S1179 D21S11 D18S51 D5S818 D13S317 D7S820
UM-SCC-104 cell line 7 X, Y 17 16, 17 24 9, 13 30, 32.2 13, 14 12 8, 9 10
UM-SCC-104 fibroblasts 4 X, Y 14, 17 16, 17 23, 24 9, 13 30, 32.2 13, 14 12 8, 9 10
Abbreviations: UM-SCC-104, University of Michigan-squamous cell carcinoma-104; AMEL-amelogenin locus - different alleles on the X and Y chromosomes; vWA-von Willebrand locus; FGA-
fibrinogen alpha locus.
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the full length E6 (476 bp) and the alternately-spliced E6*
variant (297 bp) in UM-SCC-47, Caski and UM-SCC-104
(Figure 7A). RT-PCR analysis of cDNA isolated from a
small nidus of tumor cells in frozen tissue from the
resected anterior floor of mouth tumor also demonstrated
the presence of E6 and E7 message. The level of full-
length E6 message is barely detectable with a slightly
stronger signal from the E6* alternate splice form and the
E7 signal from the frozen tissue is comparatively strong.
No E6 or E7 was detected in the HPV() UM-SCC-38
cell line. Sequencing p53 cDNA from UM-SCC-104 dem-
onstrated that the tumor cells express wild-type p53 with
the R72P polymorphism.
DISCUSSION
There are very few cell lines derived from HPV(þ)
HNSCC despite the increasing prevalence of HPV in oro-
pharyngeal cancer. To our knowledge, there are only 4
published HPV(þ) HNSCC cell lines (UM-SCC-47,
established at the University of Michigan; UD-SCC-2,
established at the University of Düsseldorf; 93-VU-147T,
established at the Free University [VU] in Amsterdam;
and UPCI-90, established at the University of
Pittsburgh).23–27 Review of the literature indicates that all
of the donors of HPV(þ) cell lines were smokers (Table
3). There are other HPVþ HNSCC cell lines, UPCI-152
established from a recurrence in the donor of UPCI-90
and UPCI 154, established from a different patient at the
University of Pittsburgh (personal communication, Sus-
anne Gollin41,42), that are available for studying HPV
oncogenesis in head and neck cancer. Herein, we present
a new HPV(þ) cell line derived from a persistent (third
recurrence) oral cavity tumor. The tumor and the cell line
both contain high-risk HPV-16 with HPV persisting in
the tumor cells in culture. This cell line, UM-SCC-104, is
a new in vitro and in vivo resource for studying conver-
gent viral and carcinogen-related pathways of carcinogen-
esis because the patient was a heavy smoker and used
alcohol for many years. Unlike many HPV(þ) tumors,
this tumor recurred after surgery and failed to respond to
chemoradiation, and thus, provides a model for use in
FIGURE 3. Identification of cancer stem cells from UM-SCC-104. (A) Flow cytometry analysis in which uptake of an aldehyde dehydrogenase
(ALDH) substrate Bodipy aminoacetaldehyde (BAAA) is inhibited with diethylaminobenzaldehyde (DEAB). This inhibition serves as a baseline for
fluorescence activity. (B) When BAAA is incubated with the cells without the inhibitor, an ALDH high population stands out (2.32%). Cells were
collected from both the ALDH high population (P5) as well as the ALDH low population (P4). (C) Five thousand cells were implanted in the flank of a
nonobese diabetic (NOD)/severe combined immunodeficiency (SCID) mouse. Cells collected in the ALDH high population grew tumor and cells from
the ALDH low population did not produce tumor. (D) Flank tumor of mouse derived from injection of ALDH high cells. [Color figure can be viewed in
the online issue, which is available at wileyonlinelibrary.com.]
TANG ET AL.
1486 HEAD &NECK—DOI 10.1002/HED OCTOBER 2012
FIGURE 4. Immunohistologic staining of the patient’s resected anterior floor of mouth tumor (primary tumor), UM-SCC-104 cancer stem cell
initiated murine xenograft tumor (CSC-derived tumor), and UM-SCC-104 cells grown on glass slides (UM-SCC-104). Sections of the primary tumor
tissue, the CSC-derived tumor and the cell line all exhibited strong and diffuse nuclear and cytoplasmic staining for p16INK4a. Cell membrane
staining was also strong and diffuse for EGFR in all three tumor cell samples. Approximately 10% of the resected tumor cells over-expressed
p53, while staining was negative for RB, Bcl-2 and cyclin D. There was 10% focal staining of RB and cyclin D and 5% focal staining for p53,
while no expression of Bcl-2 was seen on mouse tissue sections. UM-SCC-104 cultured on chamber slides uniformly over-expressed p16INK4a,
EGFR and Rb. Focal staining of cyclin D1 (20%), Bcl-2 (20%) and p53 (30%) was present in the cell line. [Color figure can be viewed in the online
issue, which is available at wileyonlinelibrary.com.]
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preclinical studies to identify potential targets for novel
therapies. Tumors like UM-SCC-104 that represent the
aggressive nonresponsive tumors are those for which new
therapies must be developed if we are to offer the
afflicted individuals more effective tumor control.
HPV(þ) tumors of the head and neck are now viewed
as a separate and biologically distinct entity from
HNSCC linked to smoking and alcohol consumption.28–30
The presence of HPV is a powerful independent predictor
of response to therapy and overall survival in patients
with HNSCC,10,11 furthermore, patients with HPV(þ)
tumors are significantly less likely to be tobacco
users.10,30,31 Hafkamp et al,7 studying a group of patients
with tonsillar cancer that were mostly smokers (84%),
observed that there was a marked difference in survival
rate between smokers and nonsmokers with HPV-associ-
ated tumors. Maxwell et al6 reported that of the oropha-
ryngeal cancer population who were HPV(þ), only about
one third were never smokers, and two thirds of patients
who were HPV(þ) were either current or former smokers.
Furthermore, never smokers had a 5-fold lower risk of
cancer progression (recurrence, distant metastasis, or sec-
ond primary cancer of the head and neck) than that of
current smokers with HPV(þ) tumors. This observation
was subsequently expanded upon in a large cooperative
trial.4 Thus, a positive tobacco history in patients with
HPV(þ) tumors may represent a distinct group of head
and neck cancers when all HNSCC are divided by etiolo-
gic factors (ie, group 1: HPV() smokers; group 2:
HPV(þ) never smokers; group 3: and HPV(þ) ever
smokers). UM-SCC-104 belongs to the group 3 demo-
graphic which have a higher risk of recurrence than
FIGURE 5. In situ hybridization for high-risk human papillomavirus (HPV) and p16INK4a immunohistochemistry staining of the patient’s tumor
tissue. (A) In situ hybridization (blue stain) demonstrating rare punctate signals (arrows) within the nucleus indicative of integrated HPV DNA. (B)
The p16INK4a immunohistochemistry demonstrating dark nuclear and diffuse cytoplasmic staining on an adjacent tumor tissue section to that used
for in situ hybridization. [Color figure can be viewed in the online issue, which is available at wileyonlinelibrary.com.]
FIGURE 6. PCR-MassARRAY analysis of HPV 16 DNA from UM-SCC-104 and the floor of mouth tumor tissue from which the cell line was
established. In each case two peak areas representing the extension products of the target allele (HPV16wt) from the tumor cells and the
corresponding competitive template allele HPV16comp) assessed by MALDI-TOF Mass Spectroscopy. The 80 Dalton mass difference between
peaks results from the single base difference between wild-type HPV16 and the HPV16 competitor.
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HPV(þ) tumors from never smokers6 supporting the need
for representative cell lines for further studies.
The creation of an HPV(þ) cell line in HNSCC is a
rare event even though the majority of oropharyngeal
tumors are now HPV(þ). For successful attachment and
subsequent in vitro propagation, it is thought that the tu-
mor cells must have acquired traits compatible with sur-
vival and immortality in the unnatural environment of in
vitro cultivation.2,8 HPV(þ) head and neck cancer cell
lines are generally from patients with aggressive tumors
that fail to respond to initial therapy. From what has been
published about the existing HPV(þ) cell lines and from
the history of UM-SCC-47, patients from which they
were derived were smokers23,27,32,33 (Table 3). Tumors
from HPV(þ) smokers may more readily accumulate the
genetic differences necessary for in vitro survival, which
may account for the aggressive tumor behavior seen in
this demographic.
UM-SCC-104 was derived from a patient who was a
welder and had an extensive smoking (20 pack/year) and
consistent moderate alcohol history. Thus, this patient had
the usual etiologic factors for head and neck cancer, but
also had a tumor that was HPV(þ). It was initially
thought that his smoking and alcohol use and the floor of
mouth primary site indicated a typical chemical carcino-
gen-induced tumor. However, upon verification of his
HPV(þ) tumor status, it became clear that there was a
more complex process involved in tumorigenesis. One
large retrospective study stratified risk factors by tumor
site and found the strongest risk for an oral cavity tumor
FIGURE 7. Reverse transcriptase polymerase chain reaction (RT-PCR) detection of human papillomavirus (HPV)-16 E6 and E7 oncogenes in cDNA
prepared from the University of Michigan-squamous cell carcinoma (UM-SCC-104) cell line, the patient’s anterior floor of mouth frozen tumor
tissue and the HPV(þ) control Caski and UM-SCC-47 cell lines. No bands were seen in HPV(-) UM-SCC-38 cell line. HPV-16 E6 primer sets amplify
the full length E6 (476 bp) and the alternately-spliced E6* variant (297 bp) in UM-SCC-47, Caski and UM-SCC-104. With the cDNA from the floor of
mouth tumor tissue the E6 bands were too faint to show in the photograph, but the E7 amplicon was more abundant and easily visible.
TABLE 3. Existing published HPV positive head and neck cancer cell lines.
Cell line Type p53 Smoking history Institute of origin
UM-SCC-47 HPV-16 Wild-type Positive University of Michigan, Ann Arbor MI
93-VU-147T HPV-16 Wild-type Positive VU Medical Center, Amsterdam Netherlands
UD-SCC-2 HPV-16 Wild-type Positive University of Dusseldorf, Dusseldorf, Germany
UPCI-SCC-90 HPV-16 Wild-type Positive University of Pittsburgh, Pittsburgh PA
Abbreviations: HPV, human papillomavirus; UM-SCC-47, University of Michigan-squamous cell carcinoma-47; VU, 93-VU-147T Vrei Universiteit tumor cell line 147T ; UD-SCC-2, University of Dus-
seldorf-squamous cell carcinoma; UPCI-SCC-90, UPCI-SCC-90 - University of Pittsburgh Cancer Institute-squamous cell carcinoma-90.
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site was alcohol, while smoking was most strongly asso-
ciated with laryngeal cancer and HPV-16 with pharyngeal
cancer.30 Had our patient tested negative for HPV, his tu-
mor would have been attributed to carcinogens related to
tobacco and alcohol usage and possibly environmental
hazards from his occupation. Our patient’s high-risk HPV
status most likely provided an additive and possibly syn-
ergistic effect with his other risk factors contributing to
the development of the cancer.34 UM-SCC-104 is a cell
line that will be an important resource to begin to investi-
gate how these combined risk factors contribute to the
formation of such a therapeutically nonresponsive tumor.
The floor of mouth is an unusual site for HPV-related
tumors. We confirmed the presence of HPV in the surgi-
cal specimen and in UM-SCC-104 using multiple meth-
ods: the patient’s recurrent tumor demonstrated integrated
HPV DNA by in situ hybridization; the tumor and the
cell line exhibited uniform overexpression of p16INK4a
(immunohistochemical analysis); E6 and E7 expression
(RT-PCR) and HPV type 16 (multiplex PCR/MALDI-
TOF mass spectroscopy) were also observed in the tumor
and the UM-SCC-104 cell line. There is currently no uni-
versal method for HPV detection in head and neck can-
cer, although numerous techniques and algorithms have
been proposed,35 and our data are unequivocal in demon-
strating that this floor of mouth/oral cavity tumor is
HPV-16 positive. Although the original site was
described as the posterior floor of the mouth and desig-
nated as an oral cavity tumor, HPV(þ) tumors of the oral
cavity are rare and it cannot be excluded that the tumor
originated in a never discovered small base of tongue tu-
mor but presented through local extension into the floor
of the mouth.
We characterized the primary tumor and UM-SCC-104
for additional HNSCC biomarkers that have been linked
to both tumor behavior and response to therapy. The tu-
mor and the cell line overexpress EGFR. We previously
reported the phenotype HPV(þ)/EGFRHigh to be associ-
ated with poorer survival after chemotherapy and radia-
tion than HPV(þ)/EGFRLow tumors.10 Cyclin D1 is also
overexpressed in a proportion of UM-SCC-104 cells.
High cyclin D1 expression is linked to poor prognosis in
head and neck cancer36 and in a clinical trial of organ-
sparing therapy for laryngeal cancer, cyclin D1 overex-
pression was a single variable that was clearly indicative
of poor survival (Bradford et al, Triologic Thesis, unpub-
lished data). Reduced expression of cyclin D1 in HPV(þ)
head and neck tumors has been reported when compared
to HPV() tumors induced by smoking and alcohol.12
This makes sense because cyclin D1 and HPV E7 onco-
protein both target Rb. The E7 oncoprotein sequesters Rb
allowing E2F-mediated transcription of the genes
involved in entry into the cell cycle to proceed unopposed
whereas cyclin D1 activates cyclin-dependent kinase that
phosphorylates Rb achieving the same effect as E7, mak-
ing both mechanisms unnecessary in the same tumor cell.
We previously reported that smoking is associated with
increased EGFR expression in oropharyngeal cancers, and
that increased EGFR expression strongly reduced the ben-
eficial effect on survival associated with HPV.10 The
increased expression of cyclin D1 in UM-SCC-104 is con-
sistent with the patient’s smoking history as well as
increased EGFR expression, because EGFR signaling acti-
vates STAT3 which in turn upregulates cyclin D1 expres-
sion37 providing an alternative mechanism of Rb activation
through cyclin dependent kinase activation. However, in
UM-SCC-104 this activation may be countered to some
degree by the E2F-driven high expression of p16INK4a,
which acts as an inhibitor of cyclin-dependent kinases.
Curiously, the proportion of biomarker-positive cells dif-
fered somewhat in the cell line and the tumor. Rb, p53,
Bcl-2, and cyclin D1 all showed higher proportions of posi-
tive cells in the cell line compared to the original tumor
specimen. Because cells with these characteristics may
have greater growth potential, it is logical that the cell line
might therefore be enriched in these types of cells particu-
larly under conditions of proliferation in vitro. There have
been conflicting data on p53 expression in HPV(þ)
HNSCC tumor cells. Some studies have observed high
expression of nuclear p53 in some HPV-containing tumors
with wild-type p5314 and other studies demonstrating low
p53 expression.38 The mechanism of overexpression of
wild-type p53 in the presence of the virus is unknown. The
expectation in HPV(þ) cells is that the E6 protein of high-
risk HPV types recruits E6-associated protein (E6AP), a
cellular ubiquitin ligase to the E6-p53-E6AP complex,
allowing ubiquitination of p53, which marks it for exporta-
tion from the nucleus and into the proteasome for degrada-
tion. Why some HPV(þ) tumors show overexpressed nu-
clear p53 is not fully understood. In UM-SCC-104 cells,
the in situ hybridization signal for HPV was not uniform
throughput the tumor suggesting that the viral genome may
have been rearranged or might be in the process of being
lost. We also noted in these cells a higher expression of an
alternate splice form of HPV E6 called E6* than of the
full-length E6 transcript. It is unknown whether the E6* is
less effective in causing p53 degradation than the full-
length E6 protein, but it is interesting to speculate that this
might be the case and thus provide an explanation for high
p53 expression in these HPV transformed tumor cells.
In accordance with the cancer stem cell theory, a small
subpopulation of high ALDH-expressing cells39 from the
UM-SCC-104 cell line was capable of forming a new tu-
mor in an immunocompromised mouse, whereas ALDH-
negative cells were unable to form a tumor. Xenotrans-
plantation is considered the gold standard for identifica-
tion of CSCs. It allows demonstration of essential CSC
characteristics including the ability for the cells to self-
renew and differentiate into various cell progeny.40 The
tumor derived from the CSCs displayed the primary tu-
mor phenotypic heterogeneity indicating that this selected
cell population has inherent stem-like functions that other
cells do not. Accordingly, we observed congruency in
biomarker expression in the mouse tumor of EGFR,
p16INK4a, cyclin D, and p53 compared to the primary
section.
CONCLUSIONS
The existence of HPV(þ) cell lines from head and
neck tumors provides opportunities to study HPV-related
carcinogenesis in head and neck cancer. UM-SCC-104 is
a new HPV(þ) cell line that also contains a small and
functionally important cancer stem cell population. This
cell line will be a valuable resource to further determine
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relevant molecular pathways in both HPV and CSC
carcinogenesis.
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